Table 1.
Subject Characteristics
| Characteristic | Arm A |
Arm B |
|---|---|---|
| ValACV Then Placebo, n = 11 | Placebo Then ValACV, n = 10 | |
| Age, yearsa | 30.4 (22.5–44.9) | 30.9 (24.5–38.5) |
| Male sex, n (%)a | 10 (90.9) | 7 (70) |
| Race, n (%)a | ||
| White | 0 (0) | 2 (20) |
| Black | 2 (22.2) | 1 (10) |
| Mixed | 7 (77.8) | 7 (70) |
| Hispanic ethnicity, n (%)a | 7 (77.8) | 7 (70) |
| Body mass index, kg/m2a | 26.2 (23–28.8) | 26.5 (24.5–27.9) |
| Baseline CD4+ T-cell count, cells/mm3a | 538 (534–650) | 635 (594–792) |
| Baseline plasma HIV-1 RNA, log10 copies/mLa | 4.39 (3.62–4.87) | 4.36 (3.76–4.61) |
Abbreviations: HIV-1, human immunodeficiency virus type 1; IQR, interquartile range; ValACV, valacyclovir.
a Presented are medians and IQR.